| For: | Kamrul-Hasan ABM, Borozan S, Jena S, Nagendra L, Dutta D, Bhattacharya S, Islam MS, Pappachan JM. Safety and efficacy of efruxifermin in metabolic dysfunction-associated steatohepatitis: A systematic review. World J Gastrointest Pharmacol Ther 2025; 16(3): 110709 [PMID: 40937291 DOI: 10.4292/wjgpt.v16.i3.110709] |
|---|---|
| URL: | https://www.wjgnet.com/2150-5349/full/v16/i3/110709.htm |
| Number | Citing Articles |
| 1 |
Mohammadjavad Sotoudeheian. Untapped potential of efruxifermin in lean MASH. Hepatology International 2025; doi: 10.1007/s12072-025-10981-6
|
| 2 |
Doha Jaber, Inas Jaber, Ayah Abu Lehia, Thekrayat Asad, Hazem Ayesh. Comparative Efficacy and Safety of Resmetirom and Efruxifermin for Metabolic Dysfunction‐Associated Steatohepatitis: A Network Meta‐Analysis of Randomized Controlled Trials. Endocrinology, Diabetes & Metabolism 2026; 9(3) doi: 10.1002/edm2.70218
|
| 3 |
Sakktivel Elangovan, Chang Chuen Mark Cheah, George Boon-Bee Goh. Incretin-based therapies: a new era in metabolic liver disease management. Hepatoma Research 2026; doi: 10.20517/2394-5079.2026.15
|